Q5173 – Injection, denosumab-adet (ponlimsi), biosimilar, 1 mg
HCPCS Level II code · Q codes: Temporary Codes
HCPCS codeQ5173
- Long description
- Injection, denosumab-adet (ponlimsi), biosimilar, 1 mg
- Short description
- Inj, denosumab-adet, 1 mg
- Pricing indicator
51Drugs- Medicare coverage
CCarrier judgment – coverage decided by the Medicare contractor- BETOS category
O1EOther drugs- Added
- October 1, 2026
- Last change
- October 1, 2026 – Added
Frequently asked questions
What is HCPCS code Q5173?
Q5173 is a HCPCS Level II code for injection, denosumab-adet (ponlimsi), biosimilar, 1 mg.
Does Medicare cover Q5173?
The HCPCS file lists coverage code C: Carrier judgment – coverage decided by the Medicare contractor. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby Q codes
- Q5165 – Injection, denosumab-mobz (oziltus), biosimilar, 1 mg
- Q5166 – Injection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg
- Q5167 – Injection, denosumab-qbde (enoby/xtrenbo), biosimilar, 1 mg
- Q5168 – Injection, ranibizumab-leyk (nufymco), biosimilar, 0.1 mg
- Q5169 – Injection, pegfilgrastim-unne (armlupeg), biosimilar, 0.5 mg
- Q5170 – Injection, aflibercept-boav (eydenzelt), biosimilar, 1 mg
- Q5171 – Injection, denosumab-mobz (boncresa), biosimilar, 1 mg
- Q5172 – Injection, filgrastim-laha (filkri), biosimilar, 1 microgram
- Q9001 – Assessment by chaplain services
- Q9002 – Counseling, individual, by chaplain services
- Q9003 – Counseling, group, by chaplain services
- Q9004 – Department of veterans affairs whole health partner services
- Q9950 – Injection, sulfur hexafluoride lipid microspheres, per ml
- Q9951 – Low osmolar contrast material, 400 or greater mg/ml iodine concentration, per ml
- Q9953 – Injection, iron-based magnetic resonance contrast agent, per ml
- Q9954 – Oral magnetic resonance contrast agent, per 100 ml
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.